Azithromycin Extended-Release (Zmax) for Sinusitis and Pneumonia
Zmax (Pfizer), an extended-release oral suspension of azithromycin, has been approved by the FDA for single dose treatment of mild to moderate community acquired pneumonia (CAP) and acute bacterial sinusitis (ABS) in adults. Immediate-release azithromycin will probably become available generically later this year when its patent expires.
...Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Azithromycin Extended-Release (Zmax) for Sinusitis and Pneumonia
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1218
Article Code: 1218b
Date: September 28, 2005
Volume: 47
Pages: 78-80
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1218
Article Code: 1218b
Date: September 28, 2005
Volume: 47
Pages: 78-80
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)